# DESCRIPTION

## FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

- disclose government sponsorship

## TECHNICAL FIELD

- introduce technical field of SARS-CoV-2 diagnosis and treatment

## BACKGROUND

- provide background on coronaviruses and SARS-CoV-2

## SUMMARY

- introduce VirScan technology
- describe epitope mapping
- discuss kinetics of epitope selection
- develop machine learning model
- detect SARS-CoV-2 exposure history
- identify public epitopes
- employ Luminex assay
- distinguish COVID-19 patients from controls
- examine history of previous viral infections
- determine correlates of COVID-19 outcomes
- describe high-throughput antibody detection methodologies
- facilitate accurate analyses of seroprevalence
- identify binding sites of anti-SARS-CoV-2 antibodies
- isolate and functionally dissect neutralizing antibodies
- analyze antibody-dependent enhancement
- compare H COVID-19 patients to NH cohorts
- describe methods for detecting SARS-CoV-2 antibodies
- provide compositions or kits for detecting SARS-CoV-2 antibodies
- describe methods for treating or reducing risk of SARS-CoV-2 infection
- provide compositions for use in treating or reducing risk of SARS-CoV-2 infection
- describe methods for generating antibodies to SARS-CoV-2
- describe methods for identifying neutralizing or non-neutralizing epitopes

## DETAILED DESCRIPTION

- introduce COVID-19 and its variability
- describe factors influencing disease severity
- highlight the importance of the immune system
- provide background on SARS-CoV-2 genome
- introduce VirScan technology
- describe antibody profiling of COVID-19 patients
- discuss cross-reactivity with other coronaviruses
- highlight the need for improved diagnostics and vaccines

### Identification of SARS-CoV-2 Epitopes Recognized by COVID Patients

- describe antibody profiling of sera from COVID-19 patients and controls
- identify public epitopes targeted by many COVID-19 patients
- map epitopes within SARS-CoV-2 using alanine scanning mutagenesis
- describe the "checkerboard" pattern of IgA and IgG antibody responses
- highlight the potential for epitope-based vaccine design

### Methods of Diagnosis: SARS-CoV-2 Signature Peptides for Detecting Seroconversion

- introduce machine learning models for predicting SARS-CoV-2 exposure history
- describe the development of a Luminex assay for detecting SARS-CoV-2 exposure
- outline the composition of the Luminex assay
- describe the methods for detecting antibody binding to epitopes
- introduce the concept of purification steps
- describe detection methods, including multiplex immunoassays
- outline the use of split enzymes reconstitution or protein-fragment complementation assays
- describe single molecule detection methods
- introduce quantitation of antibody levels
- describe the comparison of antibody levels to a disease reference
- outline the use of peptide epitopes specific for other pathogens
- describe epitope mapping for other Human coronaviruses
- introduce the concept of a reference level
- describe the determination of reference values
- outline the use of a single cut-off value or range of values
- describe the establishment of reference values based on comparative groups
- introduce the concept of a disease reference subject
- describe the use of a control reference subject
- outline the interpretation of results
- describe the potential for treatment administration
- introduce the concept of correlating antibody levels with disease severity
- describe the potential for monitoring subjects for future diseases

### Correlates of Severity in COVID-19 Patients

- introduce the goal of identifying serological elements correlating with disease severity
- describe the comparison of hospitalized and non-hospitalized COVID-19 patients
- highlight the increase in recognition of SARS-CoV-2 peptides among hospitalized patients
- discuss the potential role of viral antigen load and epitope spreading
- describe the correlation between CMV and HSV-1 seroprevalence and disease severity
- discuss the potential impact of CMV on the immune system
- describe the decrease in antibody levels against ubiquitous viruses in hospitalized patients
- highlight the potential for identifying subjects at risk of severe disease

### Methods of Improving Vaccines

- identify public and/or immunodominant epitopes
- generate vaccines with disrupted or removed epitopes
- deliver vaccines with antibodies against epitopes
- reduce production of non-protective antibodies
- boost production of protective antibodies
- associate epitopes with neutralizing antibodies
- generate vaccines with mutated SARS-CoV-2 proteins
- administer mutated proteins to mammals
- obtain antibodies from mammals
- screen antibodies and identify mutant viral proteins
- reduce generation of antibodies to non-neutralizing epitopes
- identify antibodies that induce protective immune response
- isolate and identify protective and non-protective antibodies
- formulate antibodies for administration as therapeutic
- administer antibodies to subjects with SARS-CoV-2 infection
- detect binding to non-neutralizing epitopes
- remove antibodies that bind non-neutralizing epitopes
- generate antibodies to SARS-CoV-2 using peptides

### Prophylactic and Therapeutic Compositions

- provide compositions for eliciting protective immune response
- include peptides that bind to neutralizing epitopes
- include adjuvants to increase T cell response
- administer compositions to subjects with SARS-CoV-2 infection
- administer compositions to subjects at risk of SARS-CoV-2 infection
- determine therapeutically effective amount
- determine prophylactically effective amount
- estimate dosage from cell culture assays
- formulate dosage for human use

### Kits and Compositions

- provide kits and compositions with peptides
- label and/or conjugate peptides to beads or surfaces
- use beads and surfaces for screening
- conjugate peptides to beads or surfaces
- provide pharmaceutical compositions
- include pharmaceutically acceptable carrier
- formulate compositions for parenteral administration
- formulate compositions for injectable use
- include antibacterial and antifungal agents
- include isotonic agents
- prepare sterile injectable solutions
- prepare sterile powders for injectable solutions

## EXAMPLES

- describe examples of the invention

### Materials and Methods

- introduce sources of serum used in the study
- describe cohort 1
- describe cohort 2
- describe cohort 3
- describe cohort 4
- describe cohorts 5 and 6
- describe cohorts 7 and 8
- describe cohort 9
- summarize demographic and clinical data collection

### Blood Sample Collection Methods

- describe blood sample collection for cohorts 1-3
- describe blood sample collection for cohort 4

### Design and Cloning of the Public Epitope Tiling and Alanine Scanning Library

- design public epitope tiling library
- describe alanine scanning library
- clone library into T7FNS2 vector

### Phage Immunoprecipitation and Sequencing

- describe phage immunoprecipitation and sequencing

### Gradient Boosting Machine Learning Algorithm

- train gradient boosting classifier models
- evaluate model performance using cross-validation

### High-Resolution Epitope Identification and Clustering

- generate single-amino acid resolution map of SARS-CoV-2 antibody epitopes
- identify epitopes using Hidden-Markov model
- cluster epitopes to identify unique epitopes

### Similarity-Score Calculation

- calculate similarity scores between SARS-CoV-2 and other HCoVs

### Luminex Multiplex Peptide Epitope Serology Assays

- introduce Luminex beads
- synthesize peptides with Proparglyglycine moiety
- functionalize Luminex beads with amine-PEG4-azide
- react peptides with Luminex beads using click chemistry
- perform Luminex bead-based serology assays
- incubate beads with plasma samples
- detect peptide-bound IgA or IgG
- analyze assay plates on Luminex FLEXMAP 3D instrument
- quantify peptide-specific IgA or IgG levels
- introduce ELISA serology assays
- coat 96-well plates with antigen
- block plates with PBS+3% BSA
- incubate plasma samples with plates
- detect bound IgG with anti-Human IgG-alkaline phosphatase
- quantify bound IgG by measuring OD405
- introduce VirScan library targeting human coronaviruses
- supplement library with oligonucleotides encoding peptides
- profile antibody repertoires of individuals
- analyze VirScan profiles of serum samples
- identify epitopes specific to COVID-19 patients
- introduce Luminex Multiplex Peptide Epitope Serology Assays
- develop gradient-boosting algorithm
- integrate IgG and IgA data
- predict current or past COVID-19 disease
- identify peptides from SARS-CoV-2 S and N proteins
- develop Luminex-based diagnostic for COVID-19
- choose SARS-CoV-2 peptides for Luminex assay
- couple peptides to Luminex beads
- test COVID-19 patient samples and pre-COVID-19 era controls
- develop logistic regression model
- compare Luminex assay with ELISA
- integrate only 3 SARS-CoV-2 peptides
- correlate IgG responses between Luminex and VirScan assays
- introduce Example 6
- group COVID-19 patients into hospitalized and non-hospitalized subsets
- compare responses to SARS-CoV-2 S and N peptides
- analyze Luminex assay data
- examine virome-wide VirScan data
- analyze responses to common viruses
- examine differential reactivity to CMV and HSV-1
- analyze relative strength of antibody responses
- examine demographic covariates
- analyze VirScan data for healthy donors
- introduce Example 7
- examine antibody responses to triple-alanine scanning library
- map position of HCoV S peptides
- compare frequency of peptide recognition
- use triple-alanine scanning mutagenesis
- map antibody footprints
- introduce Example 8
- use Hidden Markov Model to analyze mutagenesis data
- identify distinct epitopes across SARS-CoV-2 proteome

## OTHER EMBODIMENTS

- discuss scope of the invention

